1. Pfizer Inc.

    0 Comments Leave a Comment

    1-7 of 7
    1. Mentioned In 7 Articles

    2. Glaxo CEO Walmsley Buys Time as Strategy Gets Modest Backing

      Glaxo CEO Walmsley Buys Time as Strategy Gets Modest Backing
      (Bloomberg) -- Emma Walmsley may have bolstered her position at the top of GlaxoSmithKline Plc, at least for now, following a lukewarm reaction to long-awaited plans to restructure the pharmaceutical giant after years of underperformance.With a potential activist investor challenge looming from Elliott Management Corp., Walmsley laid out why she thinks she is the right change agent to run the pharmaceutical business that will be left once Glaxo finally carves ...
      Read Full Article
    3. Astra Plots Post-Covid Future With $39 Billion Alexion Deal

      Astra Plots Post-Covid Future With $39 Billion Alexion Deal
      (Bloomberg) -- AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. Load Error The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring away older and less profitable ...
      Read Full Article
    4. Gilead Reaches $21 Billion Deal for Immunomedics

      Gilead Reaches $21 Billion Deal for Immunomedics
      Gilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company. Gilead agreed to pay $88 a share in cash for Immunomedics, whose ...
      Read Full Article
    5. Mark Zuckerberg Asserts Control of Facebook, Pushing Aside Dissenters

      Mark Zuckerberg Asserts Control of Facebook, Pushing Aside Dissenters
      In December, Facebook Inc.'s top brass gathered at Mark Zuckerberg 's more than 700-acre, beachfront estate in Kauai, Hawaii, for an unusual board meeting to discuss how to redirect the company after years of turmoil. Changes came, but they weren't what everyone expected, according to people familiar with the gathering. Within months, Facebook announced the departure of two directors, and added a longtime friend of Mr. Zuckerberg's ...
      Read Full Article
    6. 1-7 of 7
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content